This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/resource/domain/vavai/subjekt/
n3http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://bibframe.org/vocab/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064190%3A_____%2F12%3A%230000464%21RIV13-MZ0-00064190/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064190%3A_____%2F12%3A%230000464%21RIV13-MZ0-00064190
rdf:type
n3:Vysledek skos:Concept
dcterms:description
The aim of this paper is to review and discuss current methods of risk stratification for cardiovascular disease (CVD) prevention, emerging biomarkers, and imaging techniques, and their relative merits and limitations. This report is based on discussions that took place among experts in the area during a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy in September 2009. Classical risk factors such as blood pressure and low-density lipoprotein cholesterol levels remain the cornerstone of risk estimation in primary prevention but their use as a guide to management is limited by several factors: (i) thresholds for drug treatment vary with the available evidence for cost-effectiveness and benefit-to-risk ratios; (ii) assessment may be imprecise; (iii) residual risk may remain, even with effective control of dyslipidemia and hypertension. Novel measures include C-reactive protein, lipoprotein-associated phospholipase A(2) , genetic markers, and markers of subclinical organ damage, for which there are varying levels of evidence. High-resolution ultrasound and magnetic resonance imaging to assess carotid atherosclerotic lesions have potential but require further validation, standardization, and proof of clinical usefulness in the general population. In conclusion, classical risk scoring systems are available and inexpensive but have a number of limitations. Novel risk markers and imaging techniques may have a place in drug development and clinical trial design. However, their additional value above and beyond classical risk factors has yet to be determined for risk-guided therapy in CVD prevention. The aim of this paper is to review and discuss current methods of risk stratification for cardiovascular disease (CVD) prevention, emerging biomarkers, and imaging techniques, and their relative merits and limitations. This report is based on discussions that took place among experts in the area during a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy in September 2009. Classical risk factors such as blood pressure and low-density lipoprotein cholesterol levels remain the cornerstone of risk estimation in primary prevention but their use as a guide to management is limited by several factors: (i) thresholds for drug treatment vary with the available evidence for cost-effectiveness and benefit-to-risk ratios; (ii) assessment may be imprecise; (iii) residual risk may remain, even with effective control of dyslipidemia and hypertension. Novel measures include C-reactive protein, lipoprotein-associated phospholipase A(2) , genetic markers, and markers of subclinical organ damage, for which there are varying levels of evidence. High-resolution ultrasound and magnetic resonance imaging to assess carotid atherosclerotic lesions have potential but require further validation, standardization, and proof of clinical usefulness in the general population. In conclusion, classical risk scoring systems are available and inexpensive but have a number of limitations. Novel risk markers and imaging techniques may have a place in drug development and clinical trial design. However, their additional value above and beyond classical risk factors has yet to be determined for risk-guided therapy in CVD prevention.
dcterms:title
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
skos:prefLabel
Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.
skos:notation
RIV/00064190:_____/12:#0000464!RIV13-MZ0-00064190
n3:predkladatel
n8:ico%3A00064190
n4:aktivita
n11:V
n4:aktivity
V
n4:cisloPeriodika
2
n4:dodaniDat
n10:2013
n4:domaciTvurceVysledku
n14:8395489
n4:druhVysledku
n7:J
n4:duvernostUdaju
n18:S
n4:entitaPredkladatele
n17:predkladatel
n4:idSjednocenehoVysledku
165694
n4:idVysledku
RIV/00064190:_____/12:#0000464
n4:jazykVysledku
n16:eng
n4:klicovaSlova
cardiovascular disease
n4:klicoveSlovo
n9:cardiovascular%20disease
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[B3F667C131ED]
n4:nazevZdroje
Fundamental & clinical pharmacology
n4:obor
n13:FA
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
13
n4:rokUplatneniVysledku
n10:2012
n4:svazekPeriodika
26
n4:tvurceVysledku
Cífková, Renata Zannad, F.
s:issn
0767-3981
s:numberOfPages
12
n15:doi
10.1111/j.1472-8206.2011.01023.x